Abstract
Amyloid beta (Aβ) peptides are related to the pathogenesis of Alzheimers disease (AD). The search for therapeutic strategies that lower these peptides has mainly focused on the proteolytic processing of the β-amyloid precursor protein (APP), and other post-transcriptional pathways. The transcription factor specificity protein 1 (Sp1) is vital for the regulation of several genes involved in AD including APP and the beta site APP cleaving enzyme 1 (BACE1). We have previously reported that tolfenamic acid promotes the degradation of Sp1 protein (SP1) in pancreatic human cancer cells and mice tumors. This study examines the ability of tolfenamic acid to reduce SP1 levels, and thereby decrease APP transcription and Aβ levels in rodent brains. Tolfenamic acid was administered by oral gavage to C57BL/6 mice at variable dosages and for different time periods. Results have shown that tolfenamic acid was able to downregulate brain protein levels of SP1, APP, and Aβ. These findings demonstrate that interference with upstream transcriptional pathways can lower pathogenic intermediates associated with AD, and thus tolfenamic acid represents a novel approach for the development of a therapeutic intervention for AD.
Keywords: Alzheimer's disease, amyloid beta, APP, Sp1, tolfenamic acid, transcription, APP cleaving enzyme 1, Abeta Protein Levels, migraine headaches
Current Alzheimer Research
Title: Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Volume: 8 Issue: 4
Author(s): L. I. Adwan, R. Basha, M. Abdelrahim, G. M. Subaiea and N. H. Zawia
Affiliation:
Keywords: Alzheimer's disease, amyloid beta, APP, Sp1, tolfenamic acid, transcription, APP cleaving enzyme 1, Abeta Protein Levels, migraine headaches
Abstract: Amyloid beta (Aβ) peptides are related to the pathogenesis of Alzheimers disease (AD). The search for therapeutic strategies that lower these peptides has mainly focused on the proteolytic processing of the β-amyloid precursor protein (APP), and other post-transcriptional pathways. The transcription factor specificity protein 1 (Sp1) is vital for the regulation of several genes involved in AD including APP and the beta site APP cleaving enzyme 1 (BACE1). We have previously reported that tolfenamic acid promotes the degradation of Sp1 protein (SP1) in pancreatic human cancer cells and mice tumors. This study examines the ability of tolfenamic acid to reduce SP1 levels, and thereby decrease APP transcription and Aβ levels in rodent brains. Tolfenamic acid was administered by oral gavage to C57BL/6 mice at variable dosages and for different time periods. Results have shown that tolfenamic acid was able to downregulate brain protein levels of SP1, APP, and Aβ. These findings demonstrate that interference with upstream transcriptional pathways can lower pathogenic intermediates associated with AD, and thus tolfenamic acid represents a novel approach for the development of a therapeutic intervention for AD.
Export Options
About this article
Cite this article as:
I. Adwan L., Basha R., Abdelrahim M., M. Subaiea G. and H. Zawia N., Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway, Current Alzheimer Research 2011; 8 (4) . https://dx.doi.org/10.2174/156720511795745285
DOI https://dx.doi.org/10.2174/156720511795745285 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line
Protein & Peptide Letters Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Meet Our Editorial Board Member:
Current Respiratory Medicine Reviews Sunlight Vitamin D and Skin Cancer
Anti-Cancer Agents in Medicinal Chemistry A Disposable, Highly Sensitive Biosensing System: Determination of Haptoglobin as a Significant Acute Phase Biomarker
Current Analytical Chemistry In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design Prognostic Value of Pre- and Posttreatment PET/CT Parameters in Patients Diagnosed with Advanced Stage NSCLC
Current Medical Imaging Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab
Current Cancer Drug Targets The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate
Mini-Reviews in Medicinal Chemistry Phenothiazines and Related Drugs as Multi Drug Resistance Reversal Agents in Cancer Chemotherapy Mediated by p-glycoprotein
Current Cancer Therapy Reviews Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial
Reviews on Recent Clinical Trials